HomeBiotechnology

Biotechnology

Latest news, analysis, and insights from ASX biotechnology companies

Cyclopharm’s Technegas Named as Preferred Ventilation Agent for Lung Imaging in China
Lead storyBiotechnology

Cyclopharm’s Technegas Named as Preferred Ventilation Agent for Lung Imaging in China

Cyclopharm’s Technegas unanimously recommended as China’s preferred ventilation agent for lung imaging by seven leading medical bodies.

Latest Stories — SECTOR DESK

Advertisement
Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment
Biotechnology

Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment

Syntara expands Phase 1b trial for SNT-9465, adding 10 participants, new blinded design and Sydney site; top-line data due Q1 2027 to back an IND.

LTR Pharma Final Phase II Report Confirms Fast Absorption for Spontan Intranasal Spray in Treating ED
Biotechnology

LTR Pharma Final Phase II Report Confirms Fast Absorption for Spontan Intranasal Spray in Treating ED

LTR Pharma's Spontan intranasal ED spray peaks in 10 minutes, six-fold faster than oral vardenafil; Phase II data complete, paving US licensing talks.

Vitrafy Life Sciences Expands Platelet Cryopreservation Program With Versiti Blood Health
Biotechnology

Vitrafy Life Sciences Expands Platelet Cryopreservation Program With Versiti Blood Health

Vitrafy Life Sciences expands platelet cryopreservation with Versiti; 94.4% post-thaw recovery from USAISR, two free units, US device listing aimed FY2027.

INOVIQ Defines EXO-OC Commercialisation Path after Independent Review
Biotechnology

INOVIQ Defines EXO-OC Commercialisation Path after Independent Review

INOVIQ maps a 12–18 month path to US LDT for EXO-OC after independent review; aims for H1 2028 lab validation amid sample-handling variability.

Singular Health Group Signs Deal for Florida’s First State-Funded Medical Imaging Repository
Biotechnology

Singular Health Group Signs Deal for Florida’s First State-Funded Medical Imaging Repository

Singular Health inks Florida deal for state-funded 3DICOM imaging repository with FIU, signalling first infrastructure revenue and potential Medicaid blueprint.

Nexsen Enters into Molecular GBS Diagnostic Joint Venture with FlashDx Shenzhen
Biotechnology

Nexsen Enters into Molecular GBS Diagnostic Joint Venture with FlashDx Shenzhen

Nexsen to form a 50:50 GBS diagnostic JV with FlashDx Shenzhen, targeting FDA 510(k) and EU IVDR clearance and APAC market entry.

BCAL Diagnostic Commences Phased Australian Rollout of Avantect Multi-Cancer Blood Test
Biotechnology

BCAL Diagnostic Commences Phased Australian Rollout of Avantect Multi-Cancer Blood Test

BCAL Diagnostics begins phased Australian rollout of Avantect Multi-Cancer blood test, expanding early detection across NSW, Victoria and beyond.

Genetic Signatures and Microba Life Sciences Set Commercial Terms for Merger
Biotechnology

Genetic Signatures and Microba Life Sciences Set Commercial Terms for Merger

Genetic Signatures and Microba agree all-scrip merger; MAP holders to own ~67% of the combined group at 0.654 GSS per MAP share; GSS remains ASX-listed.